Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.39 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.39 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26479501 | 0.85 | CYP19A1 (0.49) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL18427184 | 0.79 | CYP19A1 (0.49) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL21369405 | 0.79 | CYP19A1 (0.49) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL3930928 | 0.78 | KCNA5 (0.49) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL1380025 | 0.78 | KCNA5 (0.57) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL15979324 | 0.76 | CYP19A1 (0.46) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL1097922 | 0.76 | TSHR (0.46) | LMNACYP1A2CYP3A4KIF11 | |
| SCHEMBL28787569 | 0.75 | KCNA5 (0.46) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL10264542 | 0.75 | CYP19A1 (0.44) | CYP19A1TDP1LMNACYP1A2CYP3A4 | |
| SCHEMBL13557773 | 0.74 | CYP19A1 (0.55) | CYP19A1TDP1LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | YOUNGMAN MICHAEL | 2009-07-23 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CCL5, IDO1 | CYP19A1 1914/4885TDP1 2826/4885LMNA 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.